On November 1, 2022 Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, first-in-class immune-based cancer therapies designed to kill tumors and increase immune system recognition of cancers, reported that three abstracts have been selected for presentation at key upcoming clinical oncology conferences: the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 37th Annual Meeting and the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting in November (Press release, Intensity Therapeutics, NOV 1, 2022, View Source [SID1234622750]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

November 10-12: Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 37th Annual Meeting being held at the Boston Convention and Exhibition Center, Boston, MA. Two poster presentations have been selected.

Presentation 1
Abstract Number: 545
Title: A Phase II Randomized Window of Opportunity Trial Evaluating Cytotoxic and Immunomodulatory effects of Intratumoral INT230-6 (Cisplatin, Vinblastine) in Early Stage Breast Cancer: the INVINCIBLE Trial
First Author: Angel Arnaout, M.D., FACS
Session Date and Time: Thursday, November 10, 2022, 9:00 am – 9:00 pm EST
Location: Hall C; In-Person & On Demand

Presentation 2
Abstract Number: 710
Title: Safety and Survival Results From a Phase 1/2 Trial of Intratumoral Agent INT230-6 (cisplatin vinblastine) Induces Immunological Cancer Cell Death Alone or With Pembrolizumab in Patients with Refractory, Metastatic Cancers
First Author: Jacob Stephen Thomas, M.D.
Session Date and Time: Friday, November 11, 2022, 9:00 am – 9:00 pm EST
Location: Hall C; In-Person & On Demand

November 16-19: Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting being held at the Vancouver Convention Center, Vancouver BC, Canada. An oral podium presentation will be made by Matthew Ingham, M.D., Assistant Professor of Medicine in the Division of Hematology and Oncology at New York Presbyterian Hospital/Columbia University Medical Center.

Oral presentation
Abstract ID: 1301741
Title: Intratumoral INT230-6 (Cisplatin, Vinblastine, Shao) Alone or with Ipilimumab Prolonged Survival with Favorable Safety in Adults with Refractory Sarcomas (NCT03058289)
Session: Session 9: Immunology & Immunotherapy
Session Date Friday, November 18, 2022
Time: 3:30 PM – 5:00 PM PST
First Author: Matthew Ingham, M.D.

Each of the above presentations will be accessible on the "Publications, Papers and Posters" page of Intensity’s website at: View Source

About INT230-6
INT230-6, Intensity’s lead proprietary investigational product candidate, discovered using Intensity’s proprietary DfuseRx℠ technology platform, is designed to cause tumor necrosis following direct intratumoral injection. INT230-6 contains two proven, potent anti-cancer agents, cisplatin and vinblastine, with a penetration enhancer molecule, SHAO, that helps disperse the potent cytotoxic drugs throughout tumors and enable diffusion into cancer cells. Importantly, each of the active drug agents remain in the tumor causing local disease control and tumor necrosis, leading to a favorable safety profile and the induction of an anti-cancer systemic immune response, resulting in shrinkage of uninjected tumors. Immunosuppression, often seen when dosing intravenous chemotherapy, is absent when treating with INT230-6.

Study IT-01 consists of a dose escalation and several Phase 2 expansion cohorts (NCT03058289) to evaluate INT230-6 in patients with various advanced solid tumors. In 2019, the Company signed a clinical collaboration agreement with Merck Sharpe & Dohme (Merck) to evaluate the combination of INT230-6 and KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy, in patients with advanced pancreatic, colon, squamous cell and bile duct malignancies, as part of study IT-01. In 2020, the Company executed a clinical collaboration agreement with Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Bristol-Myers Squibb’s anti-CTLA-4 antibody, Yervoy (ipilimumab), in patients with advanced liver, breast and sarcoma cancers, as a separate cohort in study IT-01. In 2021, the Company executed agreements with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase 2 study in women with early stage breast cancer (the INVINCIBLE study) (NCT04781725). Over 200 patients have been enrolled in Intensity’s studies to date.